Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on March 1, 2018 the Compensation Committee of Dynavax’s Board of Directors approved the grant of inducement stock options to purchase an aggregate of 30,000 shares of common
View HTML
Toggle Summary Dynavax's HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults
HEPLISAV-B is the First and Only Two-Dose Vaccine in the U.S. for Hepatitis B Prevention in Adults
View HTML
Toggle Summary Dynavax Secures $175 Million in Non-Dilutive Debt Financing
Proceeds to be Used to Commercialize HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] in United States and Advance Company's Immuno-Oncology Product Candidates Company Deploying HEPLISAV-B Field Sales Team BERKELEY, Calif. , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies
View HTML
Toggle Summary Dynavax to Present at the RBC Capital Markets Global Healthcare Conference
BERKELEY, Calif. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray , Dynavax's chief executive officer, will participate in a fireside chat at the 2018 RBC Capital Markets Global Healthcare Conference in New York City .
View HTML
Toggle Summary Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif. , Feb. 02, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on February 1, 2018 the Compensation Committee of Dynavax's Board of Directors approved the grant of (i) inducement stock options to purchase an aggregate 98,000 shares of common
View HTML
Toggle Summary Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, Calif. , Jan. 12, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on January 10, 2018 the Compensation Committee of Dynavax's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 57,000 shares of common
View HTML
Toggle Summary Dynavax Announces HEPLISAV-B™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
HEPLISAV-B is the First and Only Two-Dose Vaccine in U.S. for Hepatitis B Prevention in Adults
View HTML
Toggle Summary Dynavax to Present at J.P. Morgan 36th Annual Healthcare Conference
BERKELEY, Calif. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that Eddie Gray , Dynavax's chief executive officer, will present at the J.P. Morgan 36th Annual Healthcare Conference next week in San Francisco, CA.
View HTML
Toggle Summary Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BERKELEY, CA -- (Marketwired) -- 12/05/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that on November 28, 2017 the Compensation Committee of Dynavax's Board of Directors approved (i) the grant of inducement stock options to purchase an aggregate 73,800 shares of common stock
View HTML
Toggle Summary Dynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
BERKELEY, CA -- (Marketwired) -- 11/27/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Eddie Gray , Dynavax's chief executive officer, will present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference this week in Boston, MA.
View HTML